2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 23:18, 18 December 2023
, 18 December 2023→Clinical Trials
| Line 293: | Line 293: | ||
NMN appears to be stable in water; in one study 93%–99% of NMN was maintained intact in drinking water at room temperature for 7–10 days.{{pmid|28068222}} | NMN appears to be stable in water; in one study 93%–99% of NMN was maintained intact in drinking water at room temperature for 7–10 days.{{pmid|28068222}} | ||
== Synergistic Supplements in Conjunction with NMN == | |||
While Nicotinamide Mononucleotide (NMN) itself is a promising compound in the realm of anti-aging and cellular health, its potential can be further enhanced when used in conjunction with other supplements. This section explores various nutraceuticals that may have synergistic effects when taken alongside NMN, potentially amplifying its benefits.{{pmid|36678315}} | |||
===3.1. Stilbenes: Resveratrol and Pterostilbene=== | |||
Stilbenes, particularly resveratrol and pterostilbene, are non-flavonoid phenolic compounds extensively studied for their anti-inflammatory, antioxidant properties, and their role in combating age-related disorders like diabetes and cancer{{pmid|23448440}}{{doi|10.7324/JAPS.2019.90717}}. They are found naturally in grapes and berries, and clinical studies have established their safety and bioavailability, with doses of resveratrol up to 5 grams and pterostilbene to 250 mg being well-tolerated{{pmid|23431291}}{{pmid|30513922}}. | |||
Despite their potential, resveratrol and pterostilbene have shown lifespan extension only in certain preclinical models, with the results being context-dependent and subject to debate{{pmid|29210129}}. Pterostilbene is particularly notable for its higher bioavailability (80%) compared to resveratrol (20%), and its efficacy in upregulating antioxidant enzymes like SOD and GR{{pmid|23691264}}. This difference in bioavailability is critical in modulating the SIRT1 pathway, with co-administration of the two potentially maximizing their collective benefits{{pmid|18826454}}. | |||
Resveratrol's role in skin health, through its anti-angiogenic and wound-healing properties, is well-documented{{pmid|23567244}}{{pmid|33949795}}, while pterostilbene effectively mitigates inflammatory responses in various contexts{{pmid|24186934}}{{pmid|24705157}}{{pmid|15832402}}{{pmid|34679686}}. | |||
The relationship between resveratrol and the SIRT1 pathway is a key focus in experimental models, especially in the context of dosage and supplementation{{doi|10.1017/S0029665113002164}}{{pmid|21613817}}. Although resveratrol has shown numerous health benefits, its direct activation of SIRT1 remains a subject of debate. Nonetheless, its indirect involvement in SIRT1 activation and its mimicry of caloric restriction effects suggest its potential as a metabolic modulator related to aging{{pmid|21569839}}{{pmid|27552971}}. | |||
Resveratrol and pterostilbene's potential in conjunction with NMN supplementation is particularly promising. Their combined use can lead to increased NAD+ levels in the heart and skeletal muscle, more so than NMN alone{{pmid|35844164}}. Resveratrol's ability to activate NMNAT1, thus increasing NAD+ levels and providing a substrate for SIRT1 activation, underscores the potential of these compounds in a targeted approach to delay or reverse aging signs{{doi|10.1038/npre.2010.4421.1}}. Their co-administration with NR has also shown a dose-dependent increase in NAD+ levels in acute kidney injury patients, further supporting their combined use in age-related therapies{{pmid|32791973}}{{pmid|29184669}}. | |||
In summary, resveratrol and pterostilbene, especially when used in combination with NMN, represent a strategic orthomolecular approach to enhancing longevity and managing age-related diseases. | |||
==Clinical Trials== | ==Clinical Trials== | ||
Starting in 2020, with the assessment of the safety of a single dose administration of NMN, there have been around 10 randomized controlled trials (RCTs) exploring the compound's effects in various contexts. The trials have varied in duration, with the longest running for 12 weeks. In terms of dosage, they have explored a range of quantities, with the highest being 1,250 mg of NMN per day and 2,000 mg (2 g) of MIB-626, a specific formulation of NMN, per day. The following table provides a comprehensive overview of these trials, detailing their design, participant demographics, dosages, and key findings: | Starting in 2020, with the assessment of the safety of a single dose administration of NMN, there have been around 10 randomized controlled trials (RCTs) exploring the compound's effects in various contexts. The trials have varied in duration, with the longest running for 12 weeks. In terms of dosage, they have explored a range of quantities, with the highest being 1,250 mg of NMN per day and 2,000 mg (2 g) of MIB-626, a specific formulation of NMN, per day. The following table provides a comprehensive overview of these trials, detailing their design, participant demographics, dosages, and key findings: | ||